Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Terminated 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Breast 1

Conditions

Sarcoma 1Non-Squamous Non-Small Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Has results × RG-1507 monoclonal antibody × Clear all
NCT00642941 2021-02-03

A Study of R1507 in Participants With Recurrent or Refractory Sarcoma

Hoffmann-La Roche

Phase 2 Terminated
317 enrolled 27 charts
Sarcoma

Sarcoma

NCT00760929 2021-01-05

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).

Hoffmann-La Roche

Phase 2 Terminated
171 enrolled 17 charts
Thoracic

Non-Squamous Non-Small Cell Lung Cancer

NCT00796107 2020-11-13

A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer

Hoffmann-La Roche

Phase 2 Terminated
6 enrolled 5 charts
Breast

Breast Neoplasms

NCT00773383 2013-06-24

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.

Hoffmann-La Roche

Phase 2 Terminated
35 enrolled 9 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡